ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer

[...]line pembrolizumab monotherapy was started at progression based on the results of ctDNA sequencing (Guardant360 assay) showing RAS wild-type, a BRAF V600E mutation, and high microsatellite instability (MSI-h). Follow-up A durable response according to Response Evaluation Criteria in Solid Tumor...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology 2023-01, Vol.24 (1), p.20-21
Main Authors: Kotani, Daisuke, Nakamura, Yoshiaki, Fujisawa, Takao, Bando, Hideaki, Sakamoto, Naoya, Johns, Amber L, Park, Keunchil, Casolino, Raffaella, Yoshino, Takayuki, Biankin, Andrew V
Format: Article
Language:English
Subjects:
Biopsy
Cancer therapies
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Colorectal Neoplasms - pathology
Genomes
Humans
Lymphatic system
Metastasis
Microsatellite instability
Monoclonal antibodies
Mutation
Non-small cell lung carcinoma
Patients
Pembrolizumab
Pharmaceuticals
Precision Medicine
Protein-tyrosine kinase
Research funding
Small cell lung carcinoma
Solid tumors
Targeted cancer therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]line pembrolizumab monotherapy was started at progression based on the results of ctDNA sequencing (Guardant360 assay) showing RAS wild-type, a BRAF V600E mutation, and high microsatellite instability (MSI-h). Follow-up A durable response according to Response Evaluation Criteria in Solid Tumors version 1.1 to combination therapy with encorafenib and cetuximab was confirmed at last follow-up (August, 2022), after more than 60 weeks of treatment. [...]treatment with ALK tyrosine kinase inhibitor alectinib was ineffective, despite the identification of an EML4–ALK fusion, which is a recognised actionable alteration in other tumour types, such as non-small cell lung cancer (NSCLC).
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(22)00650-7